PCIB — PCI Biotech Holding ASA Income Statement
0.000.00%
Last trade - 00:00- NOK13.81m
- NOK0.48m
- NOK6.74m
Annual income statement for PCI Biotech Holding ASA, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.37 | 6.27 | 4.75 | 2.99 | 6.74 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 89.5 | 92.3 | 61.2 | 25.2 | 24.7 |
| Operating Profit | -82.1 | -86 | -56.4 | -22.2 | -18 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -72.2 | -88.4 | -55.1 | -20.3 | -16.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -72.2 | -88.4 | -55.1 | -20.3 | -16.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -72.2 | -88.4 | -55.1 | -20.3 | -16.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -72.2 | -88.4 | -55.1 | -20.3 | -16.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.94 | -2.37 | -1.32 | -0.544 | -0.44 |
| Dividends per Share |